Loading...
Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways
The HER2-targeting antibody trastuzumab has shown effectiveness in treating HER2-positive breast and gastric cancers; however, its responses are limited. Currently, Nrf2 has been deemed as a key transcription factor in promoting cancer progression and resistance by crosstalk with other proliferative...
Na minha lista:
| Udgivet i: | Oxid Med Cell Longev |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Hindawi
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7387975/ https://ncbi.nlm.nih.gov/pubmed/32765809 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/9867595 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|